ZIMLAB - Zim Laboratories
📢 Recent Corporate Announcements
Zim Laboratories has successfully completed the allotment of 47,64,497 equity shares to Florintree Trinex LLP on a preferential basis. The shares were issued at a price of ₹73.46 each, resulting in a total capital infusion of approximately ₹35 crore. This allotment increases the company's paid-up equity share capital from ₹48.74 crore to ₹53.50 crore. Post-allotment, Florintree Trinex LLP holds an 8.91% stake in the company, marking the entry of a significant non-promoter investor.
- Allotted 47,64,497 equity shares at an issue price of ₹73.46 per share
- Total fundraise aggregates to approximately ₹34.99 crore from a single investor
- Paid-up equity capital expanded from ₹48.74 crore to ₹53.50 crore
- Investor Florintree Trinex LLP now holds an 8.91% stake in the company
- Issue price includes a premium of ₹63.46 per share over the face value of ₹10
Zim Laboratories Limited has finalized the dissolution of its step-down subsidiary, ZIM Laboratories Middle East DMCC, effective February 23, 2026. The closure was formally approved by the Dubai Multi Commodities Centre Authority (DMCC Authority) following an initial board approval dated August 7, 2025. This move appears to be a part of the company's internal restructuring or streamlining of its international operations. The financial impact of this closure was not disclosed in the current filing.
- Formal dissolution of ZIM Laboratories Middle East DMCC effective February 23, 2026
- Closure approved by the Dubai Multi Commodities Centre Authority (DMCC Authority)
- Follows the initial Board of Directors' approval granted on August 7, 2025
- The entity was a step-down subsidiary of Zim Laboratories Limited
ACUITE Ratings & Research Limited has reaffirmed the credit ratings for Zim Laboratories Limited's bank facilities totaling Rs 166.23 crores. The long-term rating for Rs 150.23 crores of facilities is maintained at 'ACUITE BBB' with a 'Stable' outlook. Additionally, the short-term rating for Rs 16.00 crores of facilities has been reaffirmed at 'ACUITE A3+'. This reaffirmation indicates a stable credit profile and consistent debt-servicing capability for the pharmaceutical company.
- ACUITE Ratings reaffirmed the long-term rating at 'ACUITE BBB' with a 'Stable' outlook for Rs 150.23 crores.
- The short-term rating was reaffirmed at 'ACUITE A3+' for facilities worth Rs 16.00 crores.
- Total bank facilities covered under this rating exercise amount to Rs 166.23 crores.
- The reaffirmation suggests the company's credit profile remains consistent with previous assessments.
Zim Laboratories reported a total operating income of INR 1,087 million for Q3 FY26, showing steady sequential improvement and a 23.2% YoY growth in exports. The company's EBITDA stood at INR 145 million with a margin of 13.4%, while Profit After Tax reached INR 44 million. A critical focus remains on the EU-GMP remediation process, with a regulatory audit expected in H1 FY27 to unlock high-value regulated markets. Additionally, the company raised INR 35 crores via a preferential issue to fund capacity expansion and regulatory compliance.
- Total operating income reached INR 1,087 million in Q3 FY26, driven by strong export traction.
- Export revenue grew 23.2% YoY to INR 906 million, contributing 88% of total operating income.
- Innovative NIP and OTF product segments contributed INR 132 million, representing 12.2% of revenue.
- Completed a preferential issue of INR 35 crores for pancreatin block expansion and CAPA implementation.
- EU-GMP remediation audit tentatively scheduled for H1 FY27 (June-July 2026) to address previous non-compliance.
Zim Laboratories Limited held an Extraordinary General Meeting on February 16, 2026, where shareholders approved a special resolution for the issuance of equity shares via a preferential issue on a private placement basis. The resolution was passed with an overwhelming majority, receiving 99.99% of the total votes in favor. A total of 30.74 million votes were polled, representing approximately 63.07% of the company's total outstanding shares. This approval paves the way for the company to raise capital for its strategic initiatives.
- Shareholders approved the issuance of equity shares through a preferential issue on a private placement basis via a special resolution.
- The resolution received 99.9896% votes in favor (30,734,942 votes) and only 0.0104% against.
- Total voter turnout represented 63.07% of the total 48,735,814 outstanding shares.
- Promoter group participation was 100%, with all 16,207,980 promoter shares voting in favor of the resolution.
- Public non-institutional shareholders showed strong support with 99.978% of their polled votes in favor.
Zim Laboratories Limited held its first Extraordinary General Meeting (EGM) for FY 2025-26 on February 16, 2026, to seek shareholder approval for a preferential issue of equity shares. The meeting, attended by 42 members via video conferencing, focused on a special resolution for private placement of equity. Chairman Dr. Anwar Siraj Daud addressed the shareholders regarding the proposed capital infusion and provided general business updates. The final voting results are pending the scrutinizer's report and will be disclosed to the exchanges shortly.
- Proposed a special resolution for the issuance of equity shares via preferential issue on a private placement basis.
- The EGM was conducted on February 16, 2026, with 42 shareholders participating through video conferencing.
- Chairman Dr. Anwar Siraj Daud provided updates on the company's strategic direction and the rationale for the fundraise.
- Voting was facilitated through remote e-voting and an electronic system during the meeting, with results to be announced within statutory timelines.
- The meeting was attended by key management personnel, including the CFO, Company Secretary, and representatives from Deloitte Haskins & Sells LLP.
Zim Laboratories Limited has made the audio recording of its Q3 and 9M FY26 earnings conference call available to the public. The call, held on February 13, 2026, discusses the company's financial and operational performance for the quarter and nine-month period ending December 31, 2025. This disclosure is a routine regulatory requirement under SEBI (LODR) Regulations, 2015, aimed at maintaining transparency with shareholders. Investors can access the recording through the link provided on the company's official website.
- Audio recording of Q3 & 9M FY26 earnings conference call is now accessible via the company's website.
- The disclosure is made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The recording provides management commentary on the financial results for the period ending December 31, 2025.
- The filing ensures all investors have equal access to the information shared during the institutional investor meet.
Zim Laboratories reported a recovery in Q3 FY26 with revenue growing 12.8% YoY to ₹108.66 crore. Net profit for the quarter stood at ₹4.40 crore, up 10% from ₹4.00 crore in the same period last year, showing a significant turnaround from the loss reported in the previous quarter. However, the nine-month performance remains weak, with PAT dropping over 71% YoY to ₹2.10 crore. Additionally, the company is expanding its footprint into the LATAM region by incorporating a subsidiary in Chile.
- Revenue from operations increased 12.8% YoY to ₹108.66 crore in Q3 FY26.
- Net Profit (PAT) for the quarter rose 10% YoY to ₹4.40 crore, recovering from a loss of ₹0.42 crore in Q2 FY26.
- 9M FY26 PAT stands at ₹2.10 crore, a sharp decline from ₹7.28 crore in the previous year's nine-month period.
- Board approved a $15,000 investment to set up a new wholly-owned subsidiary in Chile.
- Finance costs rose to ₹3.43 crore in Q3 FY26 compared to ₹2.73 crore in Q3 FY25.
Zim Laboratories Limited has received a GST demand notice totaling ₹2.19 crore from the Deputy Commissioner of State Tax, Nagpur. The demand pertains to the financial year 2021-22 and is based on allegations of excess Input Tax Credit (ITC) being availed. The total liability consists of ₹1.68 crore in GST, ₹34.29 lakh in interest, and ₹16.85 lakh in penalty. The company plans to file an appeal and believes there will be no material impact on its financial or operational activities.
- Total demand of ₹2,19,64,841 issued by the Deputy Commissioner of State Tax, Nagpur.
- Breakdown includes ₹1.68 crore GST, ₹34.29 lakh interest, and ₹16.85 lakh penalty.
- The order relates to alleged excess Input Tax Credit (ITC) for the FY 2021-22 period.
- Management intends to contest the demand through an appeal with the concerned authorities.
- Company noted a delay in disclosure from the receipt date of December 30, 2025, to February 11, 2026.
Zim Laboratories reported a strong sequential recovery in Q3FY26, with revenue growing 22.5% QoQ to ₹1,087 Mn and EBITDA rising 86% QoQ to ₹145 Mn. The company returned to a PAT of ₹44 Mn after a loss in Q2, largely driven by a 93% QoQ surge in the Nutraceutical segment following the resolution of currency issues in legacy markets. Despite the quarterly recovery, 9MFY26 PAT remains down 71.2% YoY at ₹21 Mn. Additionally, the board approved a ₹35 crore preferential fundraise to Florintree Trinex LLP at ₹73.46 per share.
- Q3FY26 Total Operating Income rose 12.8% YoY to ₹1,087 Mn with EBITDA margins at 13.4%.
- Nutraceutical business revenue increased 93% QoQ to ₹300 Mn, contributing 28% of total revenue.
- Board approved a preferential equity issuance of ₹35 crore to Florintree Trinex LLP at ₹73.46 per share.
- R&D spend for 9MFY26 stood at ₹230 Mn, representing 8.6% of Total Operating Income.
- CAPA remediation is nearing completion with the facility expected to be ready for inspection from March 2026.
Zim Laboratories Limited has received board approval to incorporate a wholly owned subsidiary in Chile, tentatively named ZIM Laboratories SpA. The company plans to invest up to USD 15,000 in the share capital of this new entity to facilitate business development in the LATAM region. This move marks a strategic step toward establishing a direct presence in South American pharmaceutical markets. While the initial investment is small, it provides a platform for future growth and regulatory filings in the region.
- Incorporation of a 100% wholly owned subsidiary in Chile, LATAM region.
- Initial investment approved for an amount up to USD 15,000.
- The new entity will focus on the expansion and development of the pharmaceutical business.
- Promoters Dr. Anwar Daud and Mr. Zulfiquar Kamal to be appointed as Directors of the subsidiary.
- The transaction will be a cash consideration and is currently not a related party transaction.
ZIM Laboratories reported a significant sequential recovery in Q3 FY26, with consolidated revenue growing 12.8% YoY to ₹108.66 crore. Net profit for the quarter stood at ₹4.40 crore, up from ₹4.00 crore in the same period last year and a sharp turnaround from the ₹0.42 crore loss in Q2 FY26. Despite the quarterly recovery, the nine-month (9M) performance remains pressured, with PAT down 71% YoY at ₹2.10 crore. Finance costs and other expenses have trended higher throughout the year, impacting cumulative margins.
- Revenue from operations grew 12.8% YoY to ₹108.66 crore in Q3 FY26.
- Net profit recovered to ₹4.40 crore in Q3 FY26 from a loss of ₹42.46 lakhs in the preceding quarter.
- 9-month PAT stands at ₹2.10 crore, a sharp decline from ₹7.28 crore in the previous year's 9M period.
- Finance costs for the 9-month period increased to ₹9.89 crore from ₹8.48 crore YoY.
- Total comprehensive income for Q3 FY26 was ₹5.26 crore, aided by positive other comprehensive income of ₹86.67 lakhs.
ZIM Laboratories reported a 12.8% YoY growth in revenue for Q3 FY26, reaching ₹108.66 crore. While the quarterly profit after tax (PAT) grew by 9.9% YoY to ₹4.40 crore, the cumulative nine-month performance remains under pressure with PAT down 71% compared to the previous year. Sequentially, the company showed a significant recovery, turning a profit after a loss in the preceding quarter. Additionally, the board has approved a strategic entry into the Latin American market by establishing a wholly-owned subsidiary in Chile.
- Revenue from operations increased by 12.8% YoY to ₹108.66 crore in Q3 FY26.
- Net Profit for the quarter stood at ₹4.40 crore, compared to ₹4.00 crore in the same period last year.
- Strong sequential recovery from a net loss of ₹42.46 lakhs in Q2 FY26 to a profit in Q3 FY26.
- Nine-month PAT (9M FY26) declined sharply to ₹2.10 crore from ₹7.28 crore in 9M FY25.
- Board approved an investment of up to USD 15,000 to incorporate a new subsidiary in Chile, LATAM region.
Zim Laboratories Limited has scheduled its earnings conference call for the third quarter and nine months ended December 31, 2025 (FY26). The call is set for February 13, 2026, at 10:00 AM IST and will be hosted by Go India Advisors. Key management personnel, including the Chairman and Managing Director and the CFO, will be present to discuss financial performance. Investors can pre-register via the Diamond Pass link provided in the disclosure to avoid wait times.
- Earnings call for Q3 and 9MFY26 scheduled for February 13, 2026, at 10:00 AM IST
- Management participants include CMD Dr. Anwar Siraj Daud and CFO Shyam Mohan Patro
- The session is hosted by Go India Advisors with universal dial-in numbers provided
- Discussion will focus on financial results for the quarter and nine-month period ending December 2025
Zim Laboratories has appointed Mr. Vikrant Bendre as President of International Business, leveraging his 26+ years of experience at major firms like JB Chemicals and Ipca Laboratories. The company also elevated Mr. Jitendra Pandey (VP-HR) and Mr. Sridhar Reddy (VP-Quality Assurance) to Senior Management Personnel status. Mr. Reddy’s 29 years of experience in handling US FDA and UK MHRA audits is particularly significant for the company's regulatory standing. These strategic moves are designed to bolster the company's global footprint and operational governance.
- Appointment of Vikrant Bendre as President – International Business with 26 years of global P&L experience.
- Sridhar Reddy (VP-QA) brings 29 years of experience in sterile and non-sterile pharma manufacturing and regulatory audits.
- Jitendra Pandey (VP-HR) categorized as SMP with nearly 20 years of experience from Alkem and John Deere.
- The leadership additions focus on scaling international operations and maintaining high-standard quality compliance.
Financial Performance
Revenue Growth by Segment
Total operating income for Q2 FY26 was INR 887 million, a 23.6% sequential increase. The Pharmaceutical segment contributed 83% of revenue (INR 732 million), growing 30.7% QoQ. The Nutraceutical segment contributed 17% (INR 155 million), but faced a YoY decline due to the deferment of institutional orders and softer domestic demand (INR 38 million vs INR 50 million in Q1).
Geographic Revenue Split
Exports are the primary driver, accounting for 83% of total revenue (INR 728 million in Q2 FY26), reflecting a 21% sequential improvement. Domestic business contributed approximately 17% (INR 127 million), remaining broadly stable compared to previous quarters.
Profitability Margins
Profitability showed sequential improvement with a net loss reduction from INR 19 million in Q1 FY26 to INR 4 million in Q2 FY26. This was driven by a better product mix and operational efficiencies. Operating profit margin for FY24 was 12.04%, down from 14.33% in FY23 due to higher employee costs.
EBITDA Margin
EBITDA margin for Q2 FY26 stood at 8.8%, an improvement from 7.9% in Q1 FY26. Management expects a significant jump in EBITDA during H2 FY26 to align with FY25 levels, as historically 60% of business occurs in the second half of the fiscal year.
Capital Expenditure
Total planned debt-funded capex is INR 60.42 crore as of June 30, 2025. This includes INR 40.87 crore from external debt and INR 21.53 crore from internal accruals. Specific projects include a new Tamsulosin and Dutasteride facility and the relocation of the Cephalosporin unit to meet EU-GMP standards.
Credit Rating & Borrowing
The company maintains an 'Adequate' liquidity position with ratings reaffirmed by Acuité. Borrowing includes a planned INR 40.87 crore for capex. Interest costs are a factor in the financial risk profile, which moderated in FY24 due to higher debt levels for working capital and capex.
Operational Drivers
Raw Materials
Specific chemical names and their exact percentage of total cost are not disclosed in the available documents; however, the company produces Cephalosporin, Tamsulosin, and Dutasteride formulations.
Import Sources
The company sources raw materials both internationally and from domestic suppliers within India to ensure business continuity and mitigate geopolitical risks.
Capacity Expansion
Planned expansion includes a new manufacturing facility for Tamsulosin and Dutasteride and the relocation of the Cephalosporin unit to comply with EU-GMP and WHO-GMP standards. Capex of INR 5-7 crore is also allocated for completing balance projects and INR 5 crore for CAPA implementation.
Raw Material Costs
Raw material costs are managed through a strategy of diversifying geographic presence and establishing alternative domestic sources to reduce dependence on single regions and mitigate price volatility.
Manufacturing Efficiency
Efficiency is being driven by a shift toward more digitized operations and a focus on high-margin New Innovative Products (NIP) and Oral Thin Films (OTF).
Logistics & Distribution
Distribution is global, covering 50+ countries including Asia, Africa, MENA, Latin America, and the EU. Exports account for 83% of revenue, making logistics a critical component of the cost structure.
Strategic Growth
Expected Growth Rate
0%
Growth Strategy
Growth will be achieved by completing EU-GMP remediation to unlock regulated markets, expanding the New Innovative Products (NIP) and Oral Thin Films (OTF) portfolio, and executing a robust order book in H2 FY26. The company is also pursuing contract manufacturing at alternate sites for 'Star product 1' to bypass current regulatory hurdles.
Products & Services
Small formulation dosages, sustained and controlled-release pellets, Oral Thin Films (OTF), New Innovative Products (NIP), Tamsulosin, Dutasteride, and Cephalosporin formulations.
Brand Portfolio
ZIM Laboratories, ZIM Health Technologies, ZIM Thinorals.
New Products/Services
New Innovative Products (NIP) and Oral Thin Films (OTF) contributed INR 81 million in Q2 FY26. Combined with licensing income (INR 29 million), these segments represent 19% of total operating income.
Market Expansion
Targeting high-potential developed markets in FY26, with recent investments in subsidiaries like ZIMTAS PTY LTD (Australia) and SIA ZIM Laboratories (Latvia) to strengthen local presence.
Market Share & Ranking
The company holds a 3 Star Export House Status from the Ministry of Commerce & Industry, India.
Strategic Alliances
The company uses strategic partnerships and local offices in 50+ countries; specific partner names for JVs are not disclosed.
External Factors
Industry Trends
The pharmaceutical industry is evolving toward stricter regulatory standards (EU-GMP/WHO-GMP) and innovative drug delivery systems like Oral Thin Films. ZIM is positioning itself as an innovation-led player to capture higher margins in developed markets.
Competitive Landscape
Faces intense competition from global generic players and local manufacturers in Pharmerging markets, leading to pricing pressures.
Competitive Moat
Moat is built on specialized R&D in drug delivery (OTF/NIP) and a 30-year track record in complex export markets. Sustainability depends on successfully regaining EU-GMP certification to monetize its patent/MA portfolio.
Macro Economic Sensitivity
Highly sensitive to global economic conditions and USD currency availability in 'Rest of World' (ROW) markets, which impacted the Nutra segment's ability to receive advance payments.
Consumer Behavior
Increased sensitivity toward product performance and a shift toward innovative dosage forms (sustained release/OTF) in both Pharma and Nutra segments.
Geopolitical Risks
Exposure to political instability and trade restrictions in 50+ countries. Mitigation involves geographic diversification and sourcing alternative raw materials domestically.
Regulatory & Governance
Industry Regulations
Operations are heavily impacted by EU-GMP (European Union Good Manufacturing Practices) suspension, which has delayed the innovative-led segment. Compliance with WHO-GMP and DGFT (3 Star Export House) standards is also required.
Risk Analysis
Key Uncertainties
The primary uncertainty is the timeline for EU-GMP remediation; failure to reinstate clearances will continue to stall growth in high-margin regulated markets.
Geographic Concentration Risk
83% of revenue is concentrated in export markets, with significant exposure to Pharmerging regions and the Middle East.
Third Party Dependencies
Dependency on a single customer for 14-15% of revenue and reliance on institutional orders for the Nutraceutical segment.
Technology Obsolescence Risk
The company is mitigating technology risks by investing 9.7% of revenue into R&D and shifting toward digitized manufacturing processes.
Credit & Counterparty Risk
Receivables risk is highlighted by the deterioration of the working capital cycle to 125 days and delays in receiving letters of credit from ROW customers.